Analytical Data
-
基因名
4-1BB/TNFRSF9
- Application
-
别名
CD137; ILA; TNFRSF9; 4-1BB ligand receptor; CDw137; T-cell antigen 4-1BB homolog; T-cell antigen ILA
-
种属
Human
-
表达系统
HEK293
-
标签
C- Fc
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q07011
-
表达区间
24-186aa
-
分子量
44.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
4-1BB, also known as TNFRSF9, is a member of the tumor necrosis factor receptor (TNFR) superfamily and plays a crucial role in enhancing T cell activation and survival, making it a significant target for cancer immunotherapy. Research has shown that 4-1BB expression is upregulated on activated T cells, suggesting its involvement in the costimulatory signals that promote T cell proliferation and cytotoxic activity against tumor cells. The interest in 4-1BB as a therapeutic target has intensified with the development of recombinant proteins, including agonistic antibodies and fusion proteins, aimed at stimulating the 4-1BB signaling pathway to boost anti-tumor immune responses. Studies have indicated that targeting 4-1BB can lead to improved antitumor activity and prolonged survival in various preclinical models. Moreover, the combination of 4-1BB agonists with other immunotherapeutic agents, such as checkpoint inhibitors, has shown promise in enhancing overall treatment efficacy. Understanding the structural and functional dynamics of 4-1BB is essential for the rational design of these therapeutic agents. Consequently, ongoing research into the mechanisms of action, optimal dosing regimens, and potential synergies with existing treatments will be critical for translating findings into clinical applications, ultimately aiming to improve therapeutic outcomes for cancer patients.
